ArticleInternational urology and nephrology2026
mpMRI-based clinic-radiomics-deep learning model integrating lesion and PPAT for predicting csPCa in PI-RADS category 3 lesions: a multicenter study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to the "Discrepancies in interpretation and residual confounding by dementia in studies of electrolyte impairments and frailty".International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundProstate PI-RADS category 3 lesions are indeterminate, requiring accurate tools to predict benign/malignant status and avoid unnecessary biopsies. The purpose of the study is to develop a clinical-radiomics-deep learning fusion model integrating lesions and periprostatic adipose tissue (PPAT) based on multi-parametric magnetic resonance imaging (mpMRI) for improving the detection of clinically significant prostate cancer (csPCa) in PI-RADS category 3 lesions.
methodsA total of 386 patients diagnosed with PI-RADS category 3 lesions via MRI were enrolled in this study. The cohort consisted of a training set (n=208) and an internal validation set (n=89) from Center A, as well as an external test set (n=88) from Centers B and C. Based on preprocessed prostate T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) images, prostate lesions and PPAT were separately delineated as volumes of interest (VOIs). Radiomic and deep learning features were then extracted and screened using Pearson correlation analysis, least absolute shrinkage and selection operator (LASSO) and deep feature compression. Finally, features derived from lesions and PPAT were subjected to feature concatenation and combined with specific clinical parameters to construct the final multimodal fusion model. The performance of this model was evaluated in the internal validation cohort and external test cohort using receiver operating characteristic (ROC) curves.
resultsThe fusion model integrating lesions and PPAT outperformed all single-modality models. Its AUC was 0.954 (95%CI 0.923-0.985) in the training set, 0.895 (95%CI 0.814-0.976) in the internal validation set, and 0.800 (95%CI 0.694-0.906) in the external test set. Accuracy, sensitivity, and specificity were 0.822, 0.850, and 0.814 (internal validation) and 0.818, 0.679, and 0.883 (external test), respectively.
conclusionsThe clinical-radiomics-DL fusion model based on lesions and PPAT shows promising performance for identifying csPCa in PI-RADS category 3 lesions under multicenter retrospective validation. It should be regarded as investigational auxiliary decision-making-support tool rather than ready-for-routine-clinical-use tool.
Indexed as
Identifiers
42742857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.